Nothing said here yet.
to join the conversation.
| FRANCIS LAURAChief Executive Officer | Sell | 38,006 | $762.0K | Mon, Oct 12 |
| Maheshwari AnshulChief Op & Financial Officer | Sell | 1,731 | $33.8K | Mon, Oct 5 |
| PISETSKY MICHAEL A.SVP, Ops & Adm/Chief Legal Ofr | Sell | 1,799 | $32.6K | Fri, Oct 2 |
| Maheshwari AnshulChief Op & Financial Officer | Sell | 1,758 | $32.0K | Fri, Oct 2 |
| Maheshwari AnshulChief Op & Financial Officer | Sell | 1,560 | $28.3K | Fri, Oct 2 |
| PISETSKY MICHAEL A.SVP, Ops & Adm/Chief Legal Ofr | Sell | 1,300 | $23.7K | Fri, Oct 2 |
| PISETSKY MICHAEL A.SVP, Ops & Adm/Chief Legal Ofr | Sell | 34 | $616 | Fri, Oct 2 |
| DUNN JEFFREY WDirector | Sell | 20,000 | $369.4K | Thu, Oct 1 |
| DUNN JEFFREY WDirector | Sell | 18,633 | $352.3K | Tue, Sep 1 |
| DUNN JEFFREY WDirector | Sell | 1,367 | $25.8K | Tue, Sep 1 |
| FRANCIS LAURAChief Executive Officer | Sell | 25,972 | $522.6K | Mon, Aug 24 |
| Maheshwari AnshulChief Op & Financial Officer | Sell | 11,636 | $234.0K | Mon, Aug 24 |
Why a packaging recall puts SI-BONE on watch lists SI-BONE (SIBN) is in focus after a voluntary Class II recall of certain iFuse TORQ Implant System screws, following failed tube packaging seal integrity tests that affected sterility assurance for 100…
FDA Breakthrough Device Designated (BDD) platform engineered for durable fixation in low density bone FDA Breakthrough Device Designated (BDD) platform engineered for durable fixation in low density bone
SANTA CLARA, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc.
Does Si-Bone (SIBN) have what it takes to be a top stock pick for momentum investors? Let's find out.
The mean of analysts' price targets for Si-Bone (SIBN) points to a 25.3% upside in the stock.
Record physician engagement and broad-based demand drive 15% revenue growth.
The consensus price target hints at a 38.6% upside potential for Si-Bone (SIBN).
Moby summary of SI-BONE, Inc.'s Q2 2026 earnings call
SI-BONE Inc (SIBN) delivers 15% revenue growth, narrows net loss, and raises full-year guidance on robust procedure volume and promising reimbursement tailwinds.